



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/190,887	11/12/1998	MICHEL J. N. CORMIER	ARC2589CIP1	7176

22921 7590 02/04/2002

ALZA CORPORATION
P O BOX 7210
INTELLECTUAL PROPERTY DEPARTMENT
MOUNTAIN VIEW, CA 940397210

EXAMINER	
CELSA, BENNETT M	
ART UNIT	PAPER NUMBER
1627	

DATE MAILED: 02/04/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action SummaryApplication No.
09/190,887Applicant(s)
Cormier et al.Examiner
Bennett CelsaArt Unit
1627

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE three MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on Nov 29, 2001.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-20 is/are pending in the application.
- 4a) Of the above, claim(s) 9-20 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-8 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- a) ☐ All b) ☐ Some* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- 15) ☐ Notice of References Cited (PTO-892) 18) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) ☐ Notice of Informal Patent Application (PTO-152)
- 17) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 20) ☐ Other: _____

Art Unit: 1627

DETAILED ACTION

Continued Prosecution Application

1. The request filed on 11/29/01 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/190,887 is acceptable and a CPA has been established. An action on the CPA follows.

Status of the Claims

Claims 1-20 are currently pending.

Claims 1-8 are under consideration.

Claims 9-20 are withdrawn from consideration as being directed to a nonelected invention.

2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Election/Restriction

3. Applicant's election with traverse of Group I (claims 1-8) and Applicant's election of hGH and Gly-His in Paper No. 9 is again acknowledged. The restriction and election of species requirement was made final in paper no.11 (mailed 9/12/00).

4. This application contains nonelected claims 9-20. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Art Unit: 1627

5. Claims 1-8 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

B. In claim 1, the following phrase is not understood: "the dipeptide buffer comprising a polypeptide chain of 2 to 5 amino acids". If the term "dipeptide" present in the phrase "dipeptide buffer" is being described as "a polypeptide chain of 2 to 5 amino acids" then it is confusing as to how a dipeptide can contain 3-5 amino acids and still be a dipeptide. Another possible interpretation of the phrase "the dipeptide buffer comprising a polypeptide chain of 2 to 5 amino acids" is that the buffer contains two peptides one of which is a dipeptide and the other of which is a polypeptide of 2-5 amino acids. However, the specification appears to lack any specification support. Clarification is respectfully requested.

6. Claims 1-8 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Sorensen WO 93/12812 (7/93)..

The presently claimed invention, as amended, addresses aqueous solutions "for transdermal electrotransport delivery" which comprise:

- a. A drug
- b. A dipeptide (comprising 2-5 amino acids) buffer "at which the dipeptide carries no net charge".

The solution has a pH within 1.0 pH unit of the isoelectric point (pI) of the dipeptide; and the dipeptide is preferably present in a concentration of at least about 10mM (e.g. see present claim 3)..

Art Unit: 1627

Intended use language “for transdermal electrotransport delivery” is not given patentable weight in the a composition or compound claim.

Sorensen discloses pharmaceutical compositions that comprise hGH at pH 6.5 containing His containing dipeptides, including His-Gly at a concentration of 10mM; and an electrolyte (e.g. phosphate) . See Examples 1-6 and claims 1-9.

For instance Example 2 and Table 2 on pages 19-21, discloses a composition comprising an aqueous solution comprising:

- a. The drug hGH
- b. dipeptide buffers: His-Gly (pI =6.9); His-Ala (pI=6.95); His-Leu (pI=6.95); His-Phe (pI=6.95); and His-Ser (pI=6.95) present in concentrations of 10mM and 100mM at a pH of 6.5 and 7.3.

Accordingly, the dipeptide buffers His-Gly (pI =6.9); His-Ala (pI=6.95); His-Leu (pI=6.95); His-Phe (pI=6.95); and His-Ser (pI=6.95) are all present in a solution which has a “**pH which is within 1.0 pH unit of the pI of the dipeptides**” in amounts “**of at least about 10mM; thus anticipating the presently claimed invention.** .

To the extent that the reference fails to teach the use of Gly-His as the His containing dipeptide such a selection would be immediately envisaged (e.g. anticipated) or in the alternative prima facie obvious given the reference teaching of the use of any His containing dipeptide; the exemplification of His-Gly as one of the preferred dipeptides; and the small number of possible His containing dipeptides available for selection (e.g. see the reference on page 15, lines 16-24).

Art Unit: 1627

Accordingly, the formulation of Gly-His (pI=7.5) in hGH formulations at a pH of 6.5 and 7.3 in amounts of 10mM and 100mM as in the disclosed examples (e.g. See Example 2 and Table 2) would be completely envisaged and thus anticipate the presently claimed invention; or in the alternative would be prima facie obvious in view of the Sorensen reference teaching.

See *In re Schaumann*, 572 F.2d 312. 197 USPQ 5 (CCPA 1978). Additionally, the reference dipeptide ranges e.g. 5-25 mM; 5-15 mM (e.g. see page 12, lines 19-22) would immediately envisage (e.g. anticipate) or alternatively render obvious (via optimization) the presently claimed dipeptide range of “at least about 10mM.

7. Claims 1-8 are rejected under 35 U.S.C. 103(a) as obvious over Bjorn et al. WO 97/397,768 (10/97).

The presently claimed invention, as amended, addresses aqueous solutions “for transdermal electrotransport delivery” which comprise:

- a. A drug
- b. A dipeptide (comprising 2-5 amino acids) buffer “at which the dipeptide carries no net charge”. The solution has a pH within 1.0 pH unit of the isoelectric point (pI) of the dipeptide; and the dipeptide is preferably present in a concentration of at least about 10mM (e.g. see present claim 3)..

Intended use language “for transdermal electrotransport delivery” is not given patentable weight in the a composition or compound claims.

The Bjorn et al. Reference discloses pharmaceutical aqueous compositions comprising:

Art Unit: 1627

a growth hormone (preferably hGH), a Histidine dipeptide comprising X-His or His-X (where X is one of the 19 remaining naturally occurring alpha amino acids) in a concentration of .about .01-about 10 mg/mg of GH **with optional adjustment of the pH from "about 6- about 8.8"**.

See Abstract; pages 10-13 ; and claims.

The reference disclosed dipeptides (e.g. see page 15, lines 25-30) contain pKas' of 6.9 (e.g. **His-Gly**), 7.3-7.5 (e.g. **Gly-His**, Val-His) to as high as 9.40 (His-Lys). It is noted that all of the disclosed reference dipeptides are within the scope of dipeptide buffers of the presently claimed invention.

It is also noteworthy that the Bjorn reference exemplifies hGH hormone preparations which comprise L-His at pH values from 6.1 to 6.8 which is clearly within 1 unit of the pI of L-His which is @ 7.4 (e.g. see Bjorn, Example 1 at page 18).

Optimization of pH and concentration in order to obtain optimum buffering capacity. is well within the skill of the art.

Additionally, the reference further provides explicit motivation to modify the pH within range of "about 6-8.8.

Accordingly, it would have been prima facie obvious to one of ordinary skill in the art at the time of applicant's invention to formulate aqueous composition comprising GH and Bjorn reference dipeptide buffers (e.g. His-Gly or Gly-His) within the disclosed reference pH range of about 6-8.8 to arrive at GH compositions which contain dipeptide buffers at a pH "within about 1.0 pH units of the isoelectronic point (pI)" as presently claimed.

Art Unit: 1627

8. All claims are drawn to the same invention claimed in the parent application prior to the filing of this Continued Prosecution Application under 37 CFR 1.53(d) and could have been finally rejected on the grounds and art of record in the next Office action. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing under 37 CFR 1.53(d). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

General information regarding further correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Celsa whose telephone number is (703) 305-7556.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jyothsna Venkat (art unit 1627), can be reached at (703)308-0570.

Any inquiry of a general nature, or relating to the status of this application, should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Bennett Celsa (art unit 1627)

February 1, 2002

**BENNETT CELSA
PRIMARY EXAMINER**

